Targeting Survivin and P53 in Pediatric Acute Lymphoblastic Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2011 Oct 1

PMID 21960246

Citations 28

Authors

J W Tyner

A M Jemal

M Thayer

B J Druker

B H Chang

Affiliations

Soon will be listed here.

Abstract

Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further advance treatment for this disease. RNA interference technology has identified survivin as a potential therapeutic target. Survivin, a member of the inhibitor of apoptosis (IAP) proteins and chromosome passenger complex, is expressed in hematologic malignancies and overexpressed in relapsed pediatric ALL. Our studies show that survivin is uniformly expressed at high levels in multiple pediatric ALL cell lines. Furthermore, silencing of survivin expression in pediatric ALL cell lines as well as primary leukemic blasts reduces viability of these cells. This includes cell lines derived from patients with relapsed disease featuring cytogenetic anomalies such as t(12;21), Philadelphia chromosome t(9;22), t(1;19) as well as a cell line carrying t(17;19) from a patient with de novo ALL. Furthermore, inhibition of survivin increases p53-dependent apoptosis that can be rescued by inhibition of p53. Finally, a screen of randomly selected primary patient samples confirms that survivin-specific small interfering RNA and survivin-targeted drug, YM155, effectively reduce viability of leukemic blasts.

Citing Articles

Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.

Nasrullah M, Kc R, Nickel K, Parent K, Kucharski C, Sundaram D ACS Pharmacol Transl Sci. 2024; 7(9):2840-2855.

PMID: 39296267 PMC: 11406681. DOI: 10.1021/acsptsci.4c00336.

Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.

Tripathi R, Anifowose A, Lu W, Yang X, Wang B J Enzyme Inhib Med Chem. 2022; 37(1):2370-2381.

PMID: 36043494 PMC: 9448394. DOI: 10.1080/14756366.2022.2116699.

High-Throughput Drug Library Screening in Primary -Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.

Wander P, Arentsen-Peters S, Vrenken K, Pinhanos S, Koopmans B, Dolman M Biomedicines. 2022; 10(3).

PMID: 35327440 PMC: 8945716. DOI: 10.3390/biomedicines10030638.

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

Matthijssens F, Sharma N, Nysus M, Nickl C, Kang H, Perez D J Clin Invest. 2021; 131(6).

PMID: 33555272 PMC: 7954605. DOI: 10.1172/JCI141566.

Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells.

Majera D, Mistrik M Int J Mol Sci. 2020; 21(24).

PMID: 33322336 PMC: 7763167. DOI: 10.3390/ijms21249431.

References

Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R . Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001; 32(1):119-25. DOI: 10.1053/hupa.2001.21897. View

Tyner J, Deininger M, Loriaux M, Chang B, Gotlib J, Willis S . RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A. 2009; 106(21):8695-700. PMC: 2680429. DOI: 10.1073/pnas.0903233106. View

Wang Z, Fukuda S, Pelus L . Survivin regulates the p53 tumor suppressor gene family. Oncogene. 2004; 23(49):8146-53. DOI: 10.1038/sj.onc.1207992. View

Song Z, Yao X, Wu M . Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003; 278(25):23130-40. DOI: 10.1074/jbc.M300957200. View

Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T . Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004; 314(3):902-7. DOI: 10.1016/j.bbrc.2003.12.178. View

Mirza A, McGuirk M, Hockenberry T, Wu Q, Ashar H, Black S . Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002; 21(17):2613-22. DOI: 10.1038/sj.onc.1205353. View

Bhojwani D, Kang H, Moskowitz N, Min D, Lee H, Potter J . Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006; 108(2):711-7. PMC: 1895482. DOI: 10.1182/blood-2006-02-002824. View

Mahotka C, Wenzel M, Springer E, Gabbert H, Gerharz C . Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 2000; 59(24):6097-102. View

Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai J, Vanrumbeke M . Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia. 1992; 6(1):42-6. View

10.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M . YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67(17):8014-21. DOI: 10.1158/0008-5472.CAN-07-1343. View

11.

Zhou M, Gu L, Yeager A, Findley H . Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia. 1998; 12(11):1756-63. DOI: 10.1038/sj.leu.2401198. View

12.

Zhou M, Gu L, Li F, Zhu Y, Woods W, Findley H . DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther. 2002; 303(1):124-31. DOI: 10.1124/jpet.102.037192. View

13.

Carter B, Mak D, Schober W, Cabreira-Hansen M, Beran M, McQueen T . Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2005; 107(4):1555-63. PMC: 1895411. DOI: 10.1182/blood-2004-12-4704. View

14.

Bolton M, Lan W, Powers S, McCleland M, Kuang J, Stukenberg P . Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell. 2002; 13(9):3064-77. PMC: 124143. DOI: 10.1091/mbc.e02-02-0092. View

15.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

16.

Caldas H, Jiang Y, Holloway M, Fangusaro J, Mahotka C, Conway E . Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005; 24(12):1994-2007. DOI: 10.1038/sj.onc.1208350. View

17.

Kersey J . Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997; 90(11):4243-51. View

18.

Uren A, Wong L, Pakusch M, Fowler K, Burrows F, Vaux D . Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000; 10(21):1319-28. DOI: 10.1016/s0960-9822(00)00769-7. View

19.

Fukuda S, Foster R, Porter S, Pelus L . The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood. 2002; 100(7):2463-71. DOI: 10.1182/blood.V100.7.2463. View

20.

Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S . Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 2007; 92(8):1043-50. DOI: 10.3324/haematol.10675. View